HealthDay on MSN13h
Adjuvant Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Cancer
Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...
ThePrint on MSN20h
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catch
In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...
pulmonologyadvisor21h
Keytruda Plus Chemotherapy Approved for Malignant Pleural Mesothelioma
The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.
Targeted Oncology23h
GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC
During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or ...